Accenture April 4, 2019
New Science expected to drive 54 percent of industry revenue through 2022, increase likelihood of regulatory approval of a new treatment, and raise the standard of patient care
NEW YORK: April 4, 2019 – The adoption of a unique combination of the best in science and health technology such as genomics, biomarkers and companion technologies are expected to be the biopharmaceutical industry’s new growth machine, according to new research from Accenture (NYSE: ACN).
This ‘New Science’ is filling an unmet need to advance the standard of care, and Accenture research found that companies that are leading in New Science are investing six to seven times as much money — US$250 million annually or more — in digital, data and genomics...
Today's Sponsors
Today's Sponsor